Artelo Biosciences reports Q1 EPS (78c) vs (76c) last year

“Our entire clinical and preclinical development portfolio is progressing as planned,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Significantly, our Investigational New Drug application to the U.S. Food and Drug Administration for ART26.12, our lead Fatty Acid Binding Protein 5 inhibitor for the treatment of neuropathic pain, is in the final stages of preparation.”